Published in N Engl J Med on January 28, 2010
Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles. J Allergy Clin Immunol (2012) 2.47
Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. J Clin Invest (2013) 2.15
The long quest for neonatal screening for severe combined immunodeficiency. J Allergy Clin Immunol (2012) 1.46
Positive Family History, Infection, Low Absolute Lymphocyte Count (ALC), and Absent Thymic Shadow: Diagnostic Clues for All Molecular Forms of Severe Combined Immunodeficiency (SCID). J Allergy Clin Immunol Pract (2015) 1.42
Immune responses to rotavirus infection and vaccination and associated correlates of protection. J Infect Dis (2011) 1.20
Early vs. delayed diagnosis of severe combined immunodeficiency: a family perspective survey. Clin Immunol (2010) 1.12
Bacillus Calmette-Guérin (BCG) complications associated with primary immunodeficiency diseases. J Infect (2012) 1.06
Vaccine-associated varicella and rubella infections in severe combined immunodeficiency with isolated CD4 lymphocytopenia and mutations in IL7R detected by tandem whole exome sequencing and chromosomal microarray. Clin Exp Immunol (2014) 1.03
Neonatal screening for severe combined immunodeficiency. Curr Opin Pediatr (2011) 1.02
Genetics of SCID. Ital J Pediatr (2010) 1.02
IgY antibodies protect against human Rotavirus induced diarrhea in the neonatal gnotobiotic piglet disease model. PLoS One (2012) 1.01
Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines. Biologics (2010) 1.00
The multi-systemic nature of diabetes mellitus: Genotype or phenotype? N Am J Med Sci (2010) 0.99
Real-time RT-PCR assays to differentiate wild-type group A rotavirus strains from Rotarix(®) and RotaTeq(®) vaccine strains in stool samples. Hum Vaccin Immunother (2013) 0.90
Does a monovalent inactivated human rotavirus vaccine induce heterotypic immunity? Evidence from animal studies. Hum Vaccin Immunother (2013) 0.87
Compound heterozygous CORO1A mutations in siblings with a mucocutaneous-immunodeficiency syndrome of epidermodysplasia verruciformis-HPV, molluscum contagiosum and granulomatous tuberculoid leprosy. J Clin Immunol (2014) 0.86
Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS (2017) 0.84
Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates. Vaccine (2012) 0.83
Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases. Arthritis Res Ther (2014) 0.83
Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea. PLoS Pathog (2013) 0.82
The case for newborn screening for severe combined immunodeficiency and related disorders. Ann N Y Acad Sci (2011) 0.82
Molecular diagnosis of severe combined immunodeficiency--identification of IL2RG, JAK3, IL7R, DCLRE1C, RAG1, and RAG2 mutations in a cohort of Chinese and Southeast Asian children. J Clin Immunol (2010) 0.79
Screening for severe combined immunodeficiency in neonates. Clin Epidemiol (2013) 0.79
Chronic rotavirus infection in an infant with severe combined immunodeficiency: successful treatment by hematopoietic stem cell transplantation. Clin Immunol (2011) 0.79
Evaluation of vaccines against enteric infections: a clinical and public health research agenda for developing countries. Philos Trans R Soc Lond B Biol Sci (2011) 0.79
Inhibition of rotavirus infectivity by a neoglycolipid receptor mimetic. Nutrients (2011) 0.78
Clarity and strength of implications for practice in medical journal articles: an exploratory analysis. BMJ Qual Saf (2011) 0.78
Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine. Hum Vaccin Immunother (2016) 0.76
Tandem truncated rotavirus VP8* subunit protein with T cell epitope as non-replicating parenteral vaccine is highly immunogenic. Hum Vaccin Immunother (2015) 0.76
A dual chicken IgY against rotavirus and norovirus. Antiviral Res (2012) 0.76
A new rotavirus VP6-based foreign epitope presenting vector and immunoreactivity of VP4 epitope chimeric proteins. Viral Immunol (2014) 0.75
One-step Quantitative RT-PCR Assays for Detecting, Genotyping and Differentiating Wild-Type Group a Rotaviruses and Vaccine (Rotarix(®) and RotaTeq(®)) Strains in Stool Samples. J Vaccines Vaccin (2016) 0.75
Recent advances in treatment of severe primary immunodeficiencies. F1000Res (2015) 0.75
Recurrent and Sustained Viral Infections in Primary Immunodeficiencies. Front Immunol (2017) 0.75
Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med (2006) 11.49
Rotavirus and severe childhood diarrhea. Emerg Infect Dis (2006) 7.80
A monoclonal antibody reactive with human peripheral blood monocytes. J Immunol (1980) 6.96
Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol (2003) 5.43
Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2009) 3.08
Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med (1983) 3.00
Rotavirus antigenaemia and viraemia: a common event? Lancet (2003) 2.51
Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis (2003) 1.79
Chronic rotavirus infection in immunodeficiency. J Pediatr (1980) 1.66
Extraintestinal rotavirus infections in children with immunodeficiency. J Pediatr (1992) 1.56
Delayed onset and diminished magnitude of rotavirus activity--United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep (2008) 1.51
Population-based newborn screening for severe combined immunodeficiency: steps toward implementation. J Allergy Clin Immunol (2007) 1.37
Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis. J Clin Invest (1985) 1.31
Perinatal risk factors for infant hospitalization with viral gastroenteritis. Pediatrics (1999) 1.05
Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis (2008) 1.05
Severe varicella caused by varicella-vaccine strain in a child with significant T-cell dysfunction. Pediatrics (2007) 1.02
Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. J Pediatr (1994) 1.02
Rotavirus infections in paediatric oncology patients: a matched-pairs analysis. Scand J Gastroenterol (2007) 0.89
Viremia and clinical manifestations in children with rotavirus infection. J Infect Dis (2006) 0.88
Successful treatment of disseminated BCG infection in a SCID patient with granulocyte colony stimulating factor. Asian Pac J Allergy Immunol (2008) 0.83
Sequence analysis of the VP4, VP6, VP7, and NSP4 gene products of the bovine rotavirus WC3. Virus Genes (2002) 0.83
Disseminated BCG infection resembling langerhans cell histiocytosis in an infant with severe combined immunodeficiency: a case report. Pediatr Hematol Oncol (2004) 0.81
Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr (2002) 7.79
Norovirus gastroenteritis. N Engl J Med (2009) 7.66
Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol (2003) 5.43
Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis (2002) 5.09
Laboratory efforts to cultivate noroviruses. J Gen Virol (2004) 4.41
Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch Virol (2011) 3.87
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Norwalk virus shedding after experimental human infection. Emerg Infect Dis (2008) 3.70
Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens. J Virol (2003) 3.15
Severe pneumonia due to adenovirus serotype 14: a new respiratory threat? Clin Infect Dis (2008) 3.10
Norovirus disease: changing epidemiology and host susceptibility factors. Trends Microbiol (2004) 2.83
Recommendations for the classification of group A rotaviruses using all 11 genomic RNA segments. Arch Virol (2008) 2.77
Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus. Proc Natl Acad Sci U S A (2008) 2.54
Rotavirus antigenaemia and viraemia: a common event? Lancet (2003) 2.51
Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis (2013) 2.50
The epidemiologic and clinical importance of norovirus infection. Gastroenterol Clin North Am (2006) 2.49
The 3' end of Norwalk virus mRNA contains determinants that regulate the expression and stability of the viral capsid protein VP1: a novel function for the VP2 protein. J Virol (2003) 2.38
Structural requirements for the assembly of Norwalk virus-like particles. J Virol (2002) 2.38
Norwalk virus infection associates with secretor status genotyped from sera. J Med Virol (2005) 2.34
Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis (2010) 2.21
X-ray structure of a native calicivirus: structural insights into antigenic diversity and host specificity. Proc Natl Acad Sci U S A (2006) 2.09
Rotaviruses: from pathogenesis to vaccination. Gastroenterology (2009) 2.05
Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med (2011) 2.04
Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2012) 1.98
Baseline Analysis of a Young α-1-Antitrypsin Deficiency Liver Disease Cohort Reveals Frequent Portal Hypertension. J Pediatr Gastroenterol Nutr (2015) 1.98
Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol (2003) 1.89
Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood (2012) 1.85
Neonatal infection with G10P[11] rotavirus did not confer protection against subsequent rotavirus infection in a community cohort in Vellore, South India. J Infect Dis (2007) 1.83
Inter- and intragenus structural variations in caliciviruses and their functional implications. J Virol (2004) 1.79
Evolutionary trace residues in noroviruses: importance in receptor binding, antigenicity, virion assembly, and strain diversity. J Virol (2005) 1.71
Norwalk virus RNA is infectious in mammalian cells. J Virol (2007) 1.66
Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigen. Nature (2012) 1.65
Norwalk virus-specific binding to oyster digestive tissues. Emerg Infect Dis (2006) 1.63
Long-term assessment of T-cell populations in DiGeorge syndrome. J Allergy Clin Immunol (2003) 1.63
Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr (2004) 1.60
Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr (2005) 1.57
Replication and packaging of Norwalk virus RNA in cultured mammalian cells. Proc Natl Acad Sci U S A (2005) 1.56
Identification of Genogroup I and Genogroup II broadly reactive epitopes on the norovirus capsid. J Virol (2005) 1.53
Structural analysis of histo-blood group antigen binding specificity in a norovirus GII.4 epidemic variant: implications for epochal evolution. J Virol (2011) 1.53
Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol (2013) 1.52
Comparative study of the epidemiology of rotavirus in children from a community-based birth cohort and a hospital in South India. J Clin Microbiol (2006) 1.51
Epidemiology of human noroviruses and updates on vaccine development. Curr Opin Gastroenterol (2014) 1.49
Predictors of repeat pregnancy among HIV-1-infected women. J Acquir Immune Defic Syndr (2007) 1.48
Rotavirus architecture at subnanometer resolution. J Virol (2008) 1.48
Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Clin Infect Dis (2004) 1.44
Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73: 147-157. 1993. J Immunol (2008) 1.44
Seroepidemiology of norovirus-associated travelers' diarrhea. J Travel Med (2014) 1.43
Rotavirus viremia and extraintestinal viral infection in the neonatal rat model. J Virol (2006) 1.43
Initial interaction of rotavirus strains with N-acetylneuraminic (sialic) acid residues on the cell surface correlates with VP4 genotype, not species of origin. J Virol (2002) 1.42
X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood (2010) 1.40
Cross-reactivity among several recombinant calicivirus virus-like particles (VLPs) with monoclonal antibodies obtained from mice immunized orally with one type of VLP. J Clin Microbiol (2002) 1.40
Burden of illness in the first 3 years of life in an Indian slum. J Trop Pediatr (2009) 1.40
Norwalk virus does not replicate in human macrophages or dendritic cells derived from the peripheral blood of susceptible humans. Virology (2010) 1.40
The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol (2013) 1.40
X-ray crystallographic structure of the Norwalk virus protease at 1.5-A resolution. J Virol (2006) 1.37
Antibody prevalence and titer to norovirus (genogroup II) correlate with secretor (FUT2) but not with ABO phenotype or Lewis (FUT3) genotype. J Infect Dis (2006) 1.32
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother (2006) 1.32
Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J (2006) 1.32
Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness. Nat Genet (2008) 1.31
Autophagy hijacked through viroporin-activated calcium/calmodulin-dependent kinase kinase-β signaling is required for rotavirus replication. Proc Natl Acad Sci U S A (2012) 1.30
Stem cell-derived human intestinal organoids as an infection model for rotaviruses. MBio (2012) 1.27
Norwalk virus assembly and stability monitored by mass spectrometry. Mol Cell Proteomics (2010) 1.26
Lack of norovirus replication and histo-blood group antigen expression in 3-dimensional intestinal epithelial cells. Emerg Infect Dis (2013) 1.23
Characterization of oral Yersinia enterocolitica infection in three different strains of inbred mice. Infect Immun (2004) 1.22
Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay. Clin Vaccine Immunol (2011) 1.20
Cryoelectron microscopy structures of rotavirus NSP2-NSP5 and NSP2-RNA complexes: implications for genome replication. J Virol (2006) 1.20
Partners in school asthma management: evaluation of a self-management program for children with asthma. J Sch Health (2006) 1.19
Rhinovirus associated with severe lower respiratory tract infections in children. Pediatr Infect Dis J (2009) 1.16
Standardization and performance evaluation of mononuclear cell cytokine secretion assays in a multicenter study. BMC Immunol (2006) 1.15
Integrins alpha1beta1 and alpha2beta1 are receptors for the rotavirus enterotoxin. Proc Natl Acad Sci U S A (2008) 1.15
Norwalk Virus Minor Capsid Protein VP2 Associates within the VP1 Shell Domain. J Virol (2013) 1.15
Rotavirus disrupts calcium homeostasis by NSP4 viroporin activity. MBio (2010) 1.13
Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol (2014) 1.12
Group A rotavirus infection and age-dependent diarrheal disease in rats: a new animal model to study the pathophysiology of rotavirus infection. J Virol (2002) 1.10
VLA-2 (alpha2beta1) integrin promotes rotavirus entry into cells but is not necessary for rotavirus attachment. J Virol (2002) 1.10
Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin Vaccine Immunol (2011) 1.10
The orphan granzymes of humans and mice. Curr Opin Immunol (2003) 1.09
Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning. J Allergy Clin Immunol (2009) 1.09
Golgi localization of ERManI defines spatial separation of the mammalian glycoprotein quality control system. Mol Biol Cell (2011) 1.08
Mumps resurgence in the United States. J Allergy Clin Immunol (2006) 1.07
Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. Plant Biotechnol J (2006) 1.07
Inhibition of cellular protein secretion by norwalk virus nonstructural protein p22 requires a mimic of an endoplasmic reticulum export signal. PLoS One (2010) 1.07
Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb. J Allergy Clin Immunol (2008) 1.06
Increased incidence of asthma in HIV-infected children treated with highly active antiretroviral therapy in the National Institutes of Health Women and Infants Transmission Study. J Allergy Clin Immunol (2008) 1.05
Relationship between viral load and self-report measures of medication adherence among youth with perinatal HIV infection. AIDS Care (2013) 1.03
Norovirus vaccine development: next steps. Expert Rev Vaccines (2012) 1.03
Prevalence of asthma in children and young adults with HIV infection. J Allergy Clin Immunol (2007) 1.02
The rovA mutant of Yersinia enterocolitica displays differential degrees of virulence depending on the route of infection. Infect Immun (2003) 1.02
Rapid stool-based diagnosis of Clostridium difficile infection by real-time PCR in a children's hospital. J Clin Microbiol (2011) 1.01
The VP7 outer capsid protein of rotavirus induces polyclonal B-cell activation. J Virol (2004) 1.01
Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs). Vaccine (2005) 1.01
Low rates of mother-to-child HIV transmission in a routine programmatic setting in Lilongwe, Malawi. PLoS One (2013) 1.00